Recap
Recap
Optimizing Biomarker Testing in Non–Small Cell Lung Cancer
Dr Thomas Stinchcombe discusses optimal practices for biomarker testing in non–small cell lung cancer patients to determine the best therapeutic...
Recap
Endocrine Therapy Resistance in HR+/HER2- Breast Cancer
Oncologist Jennifer Litton discusses endocrine therapy and CDK4/6 inhibitors in hormone...
Recap
Optimal Use of CDK4/6 Inhibitors in Breast Cancer
Leading oncologists discuss the role of CDK4/6 inhibitors in all stages of HR+/HER2- breast cancer, including robust results on the use of...
Recap
Frontline Treatment for Advanced HR+/HER2- Breast Cancer
Endocrine therapy plus a CDK4/6 inhibitor is now considered the standard of care for advanced HR+/HER2- breast cancer. Dr Kalinsky...
Recap
Therapeutic Approaches in Advanced Breast Cancer
Dr Susan Domchek, from the University of Pennsylvania, discusses the importance of identifying molecular characteristics of metastatic breast...
Recap
Treating High-Risk, Early-Stage HR+/HER2- Breast Cancer
Dr Michelle Melisko discusses treatment for high-risk, early-stage HR+/HER2- breast cancer, including use of genomic assays, the...
Recap
Selecting Between CDK4/6 Inhibitors in Advanced HR+/HER2- Breast Cancer
Dr Sara Hurvitz discusses efficacy, tolerability, and patient quality...
Recap
Use of Biomarkers to Optimize Treatment of NSCLC
Biomarkers have advanced the field of NSCLC by informing the choice of therapy. Physicians are urged to incorporate genetic profiling at diagnosis...
Recap
Therapeutic Approaches in Advanced Breast Cancer
Dr Susan Domchek, from the University of Pennsylvania, discusses the importance of identifying molecular characteristics of metastatic breast...
Recap
Optimal Treatment for HR+/HER2- Breast Cancer Patients With Visceral Metastasis
Dr Adam Brufsky of the University of Pittsburgh reports on alternatives to chemotherapy for patients with HR+/HER2- breast...
Recap
Latest Treatment Options in HR+/HER2- Advanced Breast Cancer in Postmenopausal Women
HR+/HER2- advanced or metastatic breast cancer may be managed with endocrine therapy combined with...